Tedizolid

DRUG4 trials

Sponsors

Assistance Publique Hopitaux De Paris, Hartford Hospital, Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center

Conditions

Bone and Joint InfectionCatheter related bloodstream infections due to Staphylococcus aureusDiabetesHealthy VolunteersPyogenic liver abscessWound Infection

Phase 1

Tedizolid Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

CompletedNCT02620787

Hartford HospitalDiabetes, Healthy Volunteers, Wound Infection

Start: 2016-02-23End: 2017-03-01Updated: 2019-01-15

Phase 2

Tolerability, Safety, and Efficacy of Tedizolid as Oral Treatment for Bone and Joint Infections (OTTER)

CompletedNCT03009045

Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical CenterBone and Joint Infection

Start: 2017-02-06End: 2021-08-06Updated: 2023-12-13

Phase 3

Randomized open-label controlled trial evaluating a single-dose intravenous Dalbavancin versus standard antibiotic therapy during catheterrelated bloodstream infections due to Staphylococcus aureus [DALICATH]

RecruitingCTIS2024-514952-34-00

Assistance Publique Hopitaux De ParisCatheter related bloodstream infections due to Staphylococcus aureus

Start: 2023-06-23Target: 406Updated: 2025-04-23

Phase 4

TIME-TO-LIA : Optimal Duration of Antibiotic Therapy in Drained Pyogenic Liver Abscess: 3 weeks versus 6 weeks, a non-inferiority trial

Not yet recruitingCTIS2025-520940-14-00

Assistance Publique Hopitaux De ParisPyogenic liver abscess

Target: 456Updated: 2025-10-06

Related Papers

Safety and tolerability of tedizolid as oral treatment for bone and joint infections

Microbiology Spectrum2023-09-2614 citations

Tedizolid phosphate for the treatment of acute bacterial skin and skin-structure infections: an evidence-based review of its place in therapy.

2019-07-0513 citations